title: High intake of folic acid or complex of B vitamins provides anti-Parkinsonism effect: no role for serum level of homocysteine.
abstract: Several lines of evidence show that homocysteine (Hcy) levels are increased in blood and CSF of patients with Parkinson's disease. B vitamins are necessary for Hcy metabolism and their deficiencies cause hyperhomocysteinemia and neurodegeneration. In present study, effect of B vitamin supplementation on the severity of 6-hydroxydopamine (6-OHDA)-induced Parkinsonism was investigated. Rats were nourished with B vitamin supplements from 1 month before of stereotaxic injection of 6-OHDA to the end of experiments. Total serum Hcy was measured at the end of experiments to identify its association with Parkinsonism. Both rotational and rotarod tests revealed that supplementation of folic acid, in a dose dependent manner, attenuates severity of Parkinsonism. Supplement of B complex also had beneficial effect and improved motor performance in rotarod test and decreased biased swings in elevated body swing test but had no effect on the apomorphine-induced rotational behavior. Supplement of B(6) attenuated rotational behavior but had no effect on the rotarod performance and swinging behavior. Supplement of B(12) or combination of folic acid with B(6) and B(12) had no effect on the behavioral symptoms of Parkinsonism. Except one group, the levels of Hcy in other vitamin B treated groups were near to that in control group. Surprisingly, Hcy in group of rats that received high intake of folic acid was significantly higher than that in control group. Our results indicate that high intake of folic acid or B complex provides anti-Parkinsonism effect but it is not mediated by lowering plasma Hcy.
authors.affiliation: Neuroscience Division, Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
authors.forename: Hashem
authors.initials: H
authors.lastname: Haghdoost-Yazdi
authors.forename: Negin
authors.initials: N
authors.lastname: Fraidouni
authors.forename: Ayda
authors.initials: A
authors.lastname: Faraji
authors.forename: Hassan
authors.initials: H
authors.lastname: Jahanihashemi
authors.forename: Mohammad
authors.initials: M
authors.lastname: Sarookhani
mesh_terms: D018663:Adrenergic Agents / Q000633:toxicity; D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D001058:Apomorphine / Q000494:pharmacology; D019540:Area Under Curve; D004195:Disease Models, Animal; D004357:Drug Synergism; D004797:Enzyme-Linked Immunosorbent Assay; D005492:Folic Acid / Q000008:administration & dosage*; D006710:Homocysteine / Q000097:blood*; D008297:Male; D016627:Oxidopamine / Q000633:toxicity; D020734:Parkinsonian Disorders / Q000097:blood* / Q000139:chemically induced / Q000178:diet therapy* / Q000503:physiopathology; D051381:Rats; D017208:Rats, Wistar; D018709:Statistics, Nonparametric; D013239:Stereotyped Behavior / Q000187:drug effects; D014803:Vitamin B Complex / Q000008:administration & dosage*
chemical_list: D018663:Adrenergic Agents; D000978:Antiparkinson Agents; D006710:Homocysteine; D014803:Vitamin B Complex; D016627:Oxidopamine; D005492:Folic Acid; D001058:Apomorphine